• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Social media bill introduced for pharma product information

Social media bill introduced for pharma product information

July 6, 2015
CenterWatch Staff

U.S. Representative Billy Long has introduced legislation to update regulations guiding how drug manufacturers communicate product information.

Long is the lead sponsor of H.R. 2479, which would force the FDA to change regulations on how pharmaceutical companies share product information with the general public. The bill would direct the FDA to clearly regulate meaningful, truthful and non-misleading communication of product information on social media. Current regulations discourage drug companies from publishing accurate informational content online, where more than half of Americans go to research medical products.

“My bill will lead to enhanced, effective and accurate communication between drug manufacturers, doctors and patients. It is now the norm to go online, whether on social media or other online platforms, and find needed information on just about anything. One would think something as important as personal decision-making for healthcare would be easy to get economic and scientific data to back up the drug's effectiveness. This bill would simply push FDA to update its regulatory approach to communications to keep up with today's technology," Long said.

Despite the popularity of Facebook and Twitter, drug manufacturers cannot confidently share, without fear of legal repercussions, product information on the online platforms with a link to detailed information. FDA deems the posts as an inadequate portrayal of product risks and benefits due to content limitation and immediate availability of detailed information. However, the FDA uses social media platforms for announcing accurate and truthful drug information.

"The FDA uses Twitter to link its announcements to more comprehensive information. It is commonsense for the federal government to allow drug manufacturers to use these platforms in a similar fashion. My bill will allow the companies, which know their products best, to state introductory information with a link to more details, just like the FDA does."

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing